---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Special populations"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Special populations. Topics: Age ranges studied in claseprubart trials; Body weight ranges studied; Pregnancy and contraception requirements in trials; Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/special-populations"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age ranges studied in claseprubart trials

> “Ages Eligible for Study 18 Years to 80 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

> “Adult males and females, 18 to 75 years of age (inclusive) at Screening.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.8-2"></a>

### Body weight ranges studied

> “Weight range between 40-130 kg at Screening”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.8-3"></a>

### Pregnancy and contraception requirements in trials

> “Female participants must be of non-childbearing potential, or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.8-4"></a>

### Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions

> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Liver test results during Screening or at check-in day (Day 1) that are elevated more than 1.5-fold above the ULN for gamma glutamyl transferase, bilirubin (total), aspartate aminotransferase (AST) or alanine aminotransferase (ALT), unless a diagnosis of Gilbert syndrome.”
> “For women of childbearing potential (WOCBP), a positive serum pregnancy test at the Screening visit or a positive urine pregnancy test (with confirmatory serum pregnancy test) at check-in (Day -1).”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
